These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25790292)

  • 1. Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: exacampania group study.
    Addeo R; Iodice P; Maiorino L; Febbraro A; Incoronato P; Pisano A; Bianco M; Mabilia R; Riccardi F; Del Prete S
    Breast J; 2015; 21(3):326-8. PubMed ID: 25790292
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching to aromatase inhibitors in early breast cancer.
    Boccardo F; Rubagotti A
    Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer: some reasons to be hopeful.
    Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
    [No Abstract]   [Full Text] [Related]  

  • 4. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 5. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine therapy in DCIS: how do we proceed?
    Dixon JM; Jane Macaskill E
    Breast J; 2012; 18(4):295-8. PubMed ID: 22759092
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
    Aapro M
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
    [No Abstract]   [Full Text] [Related]  

  • 10. The renaissance of endocrine therapy in breast cancer.
    Williams N; Harris LN
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):41-7. PubMed ID: 24346127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
    Jakesz R
    MMW Fortschr Med; 2005 Mar; 147(10):8. PubMed ID: 15803774
    [No Abstract]   [Full Text] [Related]  

  • 12. Entinostat plus exemestane has activity in ER+ advanced breast cancer.
    Cancer Discov; 2013 Jul; 3(7):OF17. PubMed ID: 23847360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does patient education work in breast cancer? Final results from the global CARIATIDE study.
    Markopoulos C; Neven P; Tanner M; Marty M; Kreienberg R; Atkins L; Franquet A; Gnant M; Neciosup S; Tesarova P; Barni S; Deschamp V
    Future Oncol; 2015; 11(2):205-17. PubMed ID: 25591836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advancement in endocrine therapy for breast cancer].
    Yang MT; Lian ZQ
    Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
    Song ST; Jiang ZF
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):510-2. PubMed ID: 16188157
    [No Abstract]   [Full Text] [Related]  

  • 16. Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
    Freedman OC; Verma S; Clemons MJ
    Breast Cancer Res Treat; 2006 Oct; 99(3):241-7. PubMed ID: 16752075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to endocrine therapy for breast cancer.
    Chlebowski RT; Geller ML
    Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anastrozole-resistant breast cancer responsive to exemestane--a case report].
    Sakurai T; Oura S; Hirai I; Tanino H; Yoshimas T; Kokawa Y; Nishida M; Sasaki R; Kinoshita T; Bessho T; Yokochi H; Nishimura O; Okamura Y
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2051-3. PubMed ID: 15570939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
    Goss PE; Richardson H; Chlebowski R; Johnston D; Sarto GE; Maunsell E; Ingle JN; Alés-Martinez JE
    Clin Breast Cancer; 2007 Dec; 7(11):895-900. PubMed ID: 18269782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.